Section Arrow
RDHL.NASDAQ
- Redhill Biopharma Ltd
Quotes are at least 15-min delayed:2024/11/10 18:59 EST
Last
 8.05
-0.11 (-1.35%)
Day High 
8.18 
Prev. Close
8.16 
1-M High
Volume 
8.90K 
Bid
7.9
Ask
8.8
Day Low
8.02 
Open
8.02 
1-M Low
7.8 
Market Cap 
10.45M 
Currency USD 
P/E 0.09 
%Yield -- 
10-SMA 8.2 
20-SMA 8.23 
50-SMA 8.88 
52-W High 82 
52-W Low 6.8 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-302.63/-1.10
Enterprise Value
10.90M
Balance Sheet
Book Value Per Share
0.05
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
6.53M
Operating Revenue Per Share
27.91
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TLRYTilray Brands1.49-0.06-3.87%-- 
ESPREsperion Therapeutics2.275+0.165+7.82%-- 
VTRSViatris12.96-0.22-1.67%227.2PE
HLNHaleon plc9.61+0.01+0.10%31.1PE
CGCCanopy Growth Corp4.24-0.31-6.81%-- 
Quotes are at least 15-min delayed:2024/11/10 18:59 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company alsocommercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.